Celldex Therapeutics, Inc. Share Price Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 277.86Cr 242.82Cr 224.07Cr 206.54Cr 389.28Cr 27TCr 397.93Cr 2.68TCr 1.05TCr 13TCr 1.04TCr 1.02TCr 45TCr | P/E 2026 * |
-8.16x | P/E 2027 * | -8.1x |
|---|---|---|---|---|---|
| Enterprise Value | 219.45Cr 191.78Cr 176.97Cr 163.12Cr 307.45Cr 21TCr 314.28Cr 2.12TCr 831.96Cr 10TCr 824.15Cr 806.06Cr 36TCr | EV / Sales 2026 * |
833x | EV / Sales 2027 * | 190x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 277.86Cr | |
| -1.29% | -3.11% | -0.39% | +4.92% | 4.97TCr | |
| +2.50% | -1.54% | +371.20% | +591.49% | 3.81TCr | |
| -1.74% | +4.72% | +7.73% | +58.06% | 3.53TCr | |
| -1.91% | -0.57% | +26.60% | -6.64% | 3.51TCr | |
| +0.06% | +1.56% | +4.41% | +27.42% | 2.72TCr | |
| +2.55% | -1.18% | - | - | 1.61TCr | |
| -0.71% | -0.41% | +67.95% | +116.69% | 1.54TCr | |
| +1.12% | +1.91% | +15.90% | +19.65% | 1.39TCr | |
| +0.04% | +1.48% | +15.88% | -30.54% | 1.3TCr | |
| Average | +1.08% | -0.57% | +63.66% | +97.63% | 2.71TCr | |
| Weighted average by Cap. | -0.16% | -0.64% | +74.30% | +118.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 26.35L 23.02L 21.25L 19.58L 36.91L 25Cr 37.73L 2.54Cr 99.89L 12Cr 98.95L 96.78L 43Cr | 1.2Cr 1.05Cr 96.47L 88.92L 1.68Cr 115.2Cr 1.71Cr 12Cr 4.54Cr 56Cr 4.49Cr 4.39Cr 194.23Cr |
| Net income | -33Cr -29Cr -27Cr -25Cr -46Cr -3.18TCr -47Cr -318.13Cr -125.13Cr -1.56TCr -123.95Cr -121.23Cr -5.36TCr | -37Cr -32Cr -30Cr -28Cr -52Cr -3.57TCr -53Cr -357.1Cr -140.46Cr -1.75TCr -139.14Cr -136.08Cr -6.02TCr |
| Net Debt | -58Cr -51Cr -47Cr -43Cr -82Cr -5.63TCr -84Cr -563.01Cr -221.44Cr -2.75TCr -219.36Cr -214.55Cr -9.48TCr | -51Cr -44Cr -41Cr -38Cr -71Cr -4.89TCr -73Cr -489.06Cr -192.36Cr -2.39TCr -190.55Cr -186.37Cr -8.24TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
